Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | PLA2G4B | P0C869 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RXRA | P19793 | 1/20 | 0.49 |
| ▸ | RXRB | P28702 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | RARB | P10826 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7256618 | 0.90 | KMT2A (0.53) | KMT2ACA1CA2TSHRMAPT | |
| Sebacic Acid SCHEMBL530379 | 0.89 | KMT2A (0.51) | KMT2ACA1CA2PLA2G4BTP53 | |
| SCHEMBL10559355 | 0.89 | KMT2A (0.51) | KMT2ACA1CA2PLA2G4BTP53 | |
| Sebacic Acid SCHEMBL3804992 | 0.89 | KMT2A (0.51) | KMT2ACA1CA2PLA2G4BTP53 | |
| SCHEMBL1952125 | 0.85 | KMT2A (0.59) | KMT2ACA1CA2PLA2G4BTP53 | |
| SCHEMBL950917 | 0.85 | KMT2A (0.63) | KMT2ACA1CA2PLA2G4BTP53 | |
| SCHEMBL14723237 | 0.84 | ELANE (0.58) | KMT2AMAPK1SRD5A2MAPTALDH1A1 | |
| SCHEMBL4684533 | 0.83 | KMT2A (0.67) | KMT2ACA1CA2PLA2G4BTP53 | |
| SCHEMBL948362 | 0.83 | KMT2A (0.67) | KMT2ACA1CA2PLA2G4BTP53 | |
| SCHEMBL27310596 | 0.83 | KMT2A (0.67) | KMT2ACA1CA2PLA2G4BTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250262146-A1 | PLATFORM NANOPARTICLE TECHNOLOGY FOR SUSTAINED DELIVERY OF HYDROPHOBIC DRUGS | UNIVERSITY OF MARYLAND, BALTIMORE | 2025-08-21 | — | — | US | claimed |
| US-20250255780-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-08-14 | — | — | US | claimed |
| EP-4514322-A1 | EXTENDED-RELEASE FORMULATION CONTAINING CRESOL | University of Maryland, Baltimore (US) | 2025-03-05 | — | — | EP | claimed |
| EP-4514395-A1 | PLATFORM NANOPARTICLE TECHNOLOGY FOR SUSTAINED DELIVERY OF HYDROPHOBIC DRUGS | University of Maryland, Baltimore (US) | 2025-03-05 | — | — | EP | claimed |
| US-12171723-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2024-12-24 | — | — | US | claimed |
| US-12029722-B2 | Dosage delivery film | Spartak LLC (US) | 2024-07-09 | — | — | US | claimed |
| WO-2023212033-A9 | EXTENDED-RELEASE FORMULATION CONTAINING CRESOL | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2024-03-28 | — | — | WO | claimed |
| US-20240050317-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | US | claimed |
| WO-2023212047-A1 | PLATFORM NANOPARTICLE TECHNOLOGY FOR SUSTAINED DELIVERY OF HYDROPHOBIC DRUGS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-11-02 | — | — | WO | claimed |
| WO-2023212033-A1 | EXTENDED-RELEASE FORMULATION CONTAINING CRESOL | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-11-02 | — | — | WO | claimed |
| WO-1997039048-A1 | PROCESS FOR THE PREPARATION OF POLYANHYDRIDES | ABBOTT LABORATORIES (US) | 1997-10-23 | — | — | WO | claimed |
| EP-0746342-A1 | BIODEGRADABLE CONTROLLED RELEASE MELT-SPUN DELIVERY SYSTEM | FUISZ TECHNOLOGIES LTD. (US) | 1996-12-11 | — | — | EP | claimed |
| EP-0260415-B1 | Synthesis and application of high molecular weight polyanhydrides | MASSACHUSETTS INST TECHNOLOGY (US) | 1996-11-27 | — | — | EP | claimed |
| EP-0535387-B1 | Echographique particle, preparation and application | HOECHST AG (DE) | 1996-08-21 | — | — | EP | claimed |
| US-5518730-A | Biodegradable controlled release flash flow melt-spun delivery system | FUISZ TECHNOLOGIES LTD. (US) | 1996-05-21 | — | — | US | claimed |
| EP-0692510-A1 | Preparation of anhydride copolymers | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1996-01-17 | — | — | EP | claimed |
| EP-0746342-A4 | BIODEGRADABLE CONTROLLED RELEASE MELT-SPUN DELIVERY SYSTEM | FUISZ TECHNOLOGIES LTD (US) | 1996-01-11 | — | — | EP | claimed |
| WO-1993024154-A1 | BIODEGRADABLE CONTROLLED RELEASE MELT-SPUN DELIVERY SYSTEM | FUISZ TECHNOLOGIES, LTD. (US) | 1993-12-09 | — | — | WO | claimed |
| EP-0535387-A1 | Echographique particle, preparation and application | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-04-07 | — | — | EP | claimed |
| EP-0266603-A1 | Preparation of anhydride copolymers | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1988-05-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250262146-A1 | PLATFORM NANOPARTICLE TECHNOLOGY FOR SUSTAINED DELIVERY OF HYDROPHOBIC DRUGS | VEGFA, LDHA, LDHB | KMT2A 2609/4885CA1 2698/4885CA2 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.